Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.8
Journals
Pharmaceuticals
Special Issues
Advances in Hydrazone Compounds with Anticancer Activity
share announcement

Advances in Hydrazone Compounds with Anticancer Activity

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 4265

Special Issue Editors

Dr. Boryana Nikolova-Mladenova

E-Mail Website
Guest Editor
Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria
Interests: hydrazones; anticancer activity; metal complexes; lipophilicity; structure–activity relations
Prof. Dr. Mariyana Atanasova

E-Mail Website
Guest Editor
Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria
Interests: drug design; molecular docking; molecular dynamics; hydrazones; anticancer activity; structure–activity relations
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hydrazones, characterized by their R-C=N-NH-R' linkage, are attracting widespread attention in medicinal chemistry as a promising class of anticancer agents. Their structural simplicity, synthetic accessibility, and diverse pharmacological activities have prompted extensive research into their anticancer potential. One important trend in this domain is the development of novel hydrazone derivatives with enhanced potency and selectivity, with structural modifications—such as the incorporation of heterocyclic rings, introduction of halogen atoms, and optimization of substituent groups, including methoxy, methyl, and amino groups—serving as strategies. Another means by which to increase activity is to include hydrazones as ligands in various metal complexes. A key area of research is therefore understanding their mechanisms of action. The conjugation of hydrazones with nanoparticles is also being examined to ensure the precise targeting of the tumor while minimizing systemic toxicity and maximizing therapeutic concentration at target sites.

This Special Issue focuses on advances in the design, synthesis, and anticancer activity of novel hydrazones and their metal complexes. Authors are encouraged to contribute original research articles, reviews, and short communications examining hydrazones that selectively target specific cancer hallmarks, leading to improved efficacy and reduced off-target effects.

Dr. Boryana Nikolova-Mladenova
Prof. Dr. Mariyana Atanasova
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hydrazones
  • lipophilicity
  • logP
  • anticancer activity
  • selectivity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

31 pages, 3933 KB  
Article
Design, Synthesis, and Biological Evaluation of N-Acyl-Hydrazone-Linked Quinazolinone Derivatives with Antioxidant, Antimicrobial, and Anticancer Potential
by Maria Coandă, Constantin Drăghici, Lucia Pintilie, Erzsébet-Eleonóra Kapronczai, Cornel Chiriță, Ioana-Cristina Marinaș, Robert-Viorel Ancuceanu, Irina Zarafu, Petre Ioniță, Denisa-Ioana Crăciun, Ariana Hudiță, Bianca Gălățeanu, Carmen Limban and Diana Camelia Nuță
Pharmaceuticals 2026, 19(1), 57; https://doi.org/10.3390/ph19010057 - 26 Dec 2025
Viewed by 1296
Abstract
Objectives: Combining two pharmacophores into one molecule with multiple applications presents interest in the field of medicinal chemistry. Quinazolinones are among privileged scaffolds due to their wide biological activities, whereas hydrazones are versatile linkers with pharmacological potential. Thus, this article focused on [...] Read more.
Objectives: Combining two pharmacophores into one molecule with multiple applications presents interest in the field of medicinal chemistry. Quinazolinones are among privileged scaffolds due to their wide biological activities, whereas hydrazones are versatile linkers with pharmacological potential. Thus, this article focused on a green method for the synthesis of new N-acyl-hydrazones of 2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide and the exploration of their biological potential. Methods: The novel N-acyl-hydrazones (1a–1f) were synthesized under microwave irradiation, using various substituted salicylaldehydes and benzaldehydes. The products were characterized by FT-IR, 1H-NMR, 13C-NMR, and HRMS. Their pharmacological profile was assessed by in silico methods and docking simulations. Biological evaluation included antioxidant, antimicrobial, and cytotoxic activities, as well as preliminary toxicity on Artemia franciscana. Results: Spectroscopic data indicated syn-E and anti-E isomers. Compound 1c showed the highest antioxidant activity. Antimicrobial assays indicated narrow-spectrum activity, with compounds 1a and 1b being most effective against C. albicans and S. aureus. Biofilm inhibition assays revealed that 1a and 1c interfered with microbial adhesion, highlighting their potential in combating biofilm-associated infections. Cytotoxicity tests on HT-29 and A431 cancer cell lines showed selective anticancer effects for compounds 1a–1d, with minimal toxicity on normal Vero cells, especially for 1b and 1d. Toxicity against Artemia franciscana correlated with in vitro cytotoxicity data, revealing low lethality for all N-acyl-hydrazones. Docking studies indicate that the antibacterial activity may involve inhibition of S. aureus DNA gyrase B, whereas the cytotoxic effects could be mediated by interaction with the EGFR kinase. Conclusions: These findings may increase the chances of identifying a lead compound in this class, supporting the further development of selected N-acyl-hydrazones and their pharmacological exploration. Full article
(This article belongs to the Special Issue Advances in Hydrazone Compounds with Anticancer Activity)
►▼ Show Figures

Graphical abstract

24 pages, 1620 KB  
Article
Novel Indole-Based Sulfonylhydrazones as Potential Anti-Breast Cancer Agents: Synthesis, In Vitro Evaluation, ADME, and QSAR Studies
by Violina T. Angelova, Rositsa Mihaylova, Zvetanka Zhivkova, Nikolay Vassilev, Boris Shivachev and Irini Doytchinova
Pharmaceuticals 2025, 18(8), 1231; https://doi.org/10.3390/ph18081231 - 20 Aug 2025
Cited by 1 | Viewed by 2104
Abstract
Background: Breast cancer continues to pose a significant global health challenge despite advances in early detection and targeted therapies. The development of novel chemotherapeutic agents remains crucial, particularly those with selective cytotoxicity toward specific breast cancer subtypes. Methods: A series of [...] Read more.
Background: Breast cancer continues to pose a significant global health challenge despite advances in early detection and targeted therapies. The development of novel chemotherapeutic agents remains crucial, particularly those with selective cytotoxicity toward specific breast cancer subtypes. Methods: A series of ten hybrid indolyl-methylidene phenylsulfonylhydrazones and one bis-indole derivative were designed, synthesized, and structurally characterized using NMR and high-resolution mass spectrometry (HRMS). Prior to synthesis, in silico screening was performed to assess drug likeness and ADME-related properties. Single-crystal X-ray diffraction was conducted for compound 3e. The cytotoxic potential of the synthesized compounds was evaluated using the MTT assay against MCF-7 (ER-α⁺) and MDA-MB-231 (triple-negative) breast cancer cell lines. Additionally, quantitative structure–activity relationship (QSAR) analysis was conducted to identify key structural features contributing to activity. Results: Most compounds exhibited selective cytotoxicity against MCF-7 cells. Notably, compound 3b demonstrated the highest potency with an IC50 of 4.0 μM and a selectivity index (SI) of 20.975. Compound 3f showed strong activity against MDA-MB-231 cells (IC50 = 4.7 μM). QSAR analysis revealed that the presence of a non-substituted phenyl ring and specific indolyl substituents (5-methoxy, 1-acetyl, 5-chloro) significantly contributed to enhanced cytotoxic activity and ligand efficiency. Conclusion: The synthesized phenylsulfonylhydrazone hybrids exhibit promising and selective cytotoxicity, particularly against ER-α⁺ breast cancer cells. Structural insights from QSAR analysis provide a valuable foundation for the further optimization of this scaffold as a potential source of selective anticancer agents. Full article
(This article belongs to the Special Issue Advances in Hydrazone Compounds with Anticancer Activity)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop